Category: Vaccine

Page 29«..1020..28293031..4050..»

Here’s how U.S. health officials are responding to bird flu in humans after second case – CNBC

May 25, 2024

Cows are seen standing in a feedlot on June 14, 2023 in Quemado, Texas.

Brandon Bell | Getty Images

H5N1 has been spreading among more animal species worldwide since 2020, but its detection in U.S. livestock earlier this year was a twist health officials did not expect. In rare cases, bird flu viruses spread to humans and can cause mild to severe symptoms that can require hospitalization.

There is currently no evidence that H5N1 is spreading from person to person. The Centers for Disease Control and Prevention has also said the risk of infection is higher among farmworkers than in the general population.

Still, the U.S. government, along with state and local health departments, are monitoring new and emerging infections among humans and animals. Federal agencies in the U.S. and elsewhere have also tracked the H5N1 virus for years to monitor its evolution.

The U.S. government has long stockpiled vaccines and drugs to be used in a possible bird flu pandemic. Last week, it started the process of preparing nearly 5 million doses of vaccines expected to be well-matched against H5N1, among other efforts to respond, the Health and Human Services Department confirmed to CNBC.

Some infectious disease experts told CNBC the U.S. government appears to be generally prepared if bird flu begins to spread more widely and easily to humans, especially compared with how equipped the country was for the Covid pandemic. The experts said most of the necessary tools are already on hand but the government must ensure it deploys them effectively, if needed.

"There's a lot of pieces that are already in place that help us understand that we can respond to this faster," said Dr. Andrew Pekosz, a professor at the Johns Hopkins Bloomberg School of Public Health. "As is always the case, though, it's about the efficiency of our responses, right? We know what we can do. We just have to be able to do it effectively."

The latest human infection, in the Michigan dairy worker, is not a surprise, according to both experts and the government. The CDC said Wednesday that similar cases in humans could be identified because high levels of the virus have been found in raw milk from infected cows.

The U.S. government currently has two vaccine virus candidates that it believes are a good match for H5N1. Those candidates are weakened versions of a virus that trigger a protective immune response against it in the body and can be used to produce vaccines.

Both of the candidates are already available to manufacturers, according to the CDC. The government last week started the process of manufacturing 4.8 million doses of those human vaccines in case they are needed, HHS confirmed.

Pekosz called those doses a "first line of defense in case we do see some human-to-human transmission." He said that number is enough to stem an outbreak in its early stages, which could include vaccinating farm workers and some health-care workers.

But he said far more are needed for the more than 300 million people in the U.S. if the virus spreads widely among humans.

"Five million doesn't really get us very far. It's just a quick start," Pekosz said.

U.S. health officials said May 1 that the government could ship more than 100 million doses of human bird flu vaccines within three to four months if needed, NBC News reported.

Notably, people will need two doses of a vaccine, meaning that 100 million doses is enough for only 50 million people. That suggests the U.S. would need roughly 600 million shots if it wanted to vaccinate the entire population.

The government faces a difficult decision on how many shots to prepare, especially since it takes a few months to make them.

"It's either too little or too much. For example, if you make too much food, then a lot of food goes to waste," said Dr. Peter Chin-Hong, an infectious disease physician at UCSF Health. "That's really the whole big conundrum now with a vaccine whenever you have a potential threat. It's the high cost and high-risk aspects."

Chin-Hong said misinformation and vaccine hesitancy after Covid makes that decision all the more challenging. But he said he believes "you can never really invest too much" in preparing for potential pandemics, especially at a time when climate change, population growth and other factors make them increasingly likely to happen.

The Food and Drug Administration would need to approve bird flu vaccines before they roll out. But Pekosz said that will likely be a "rapid procedure" since the FDA is accustomed to clearing seasonal flu vaccines, which are made using the same manufacturing process as bird flu shots.

U.S. health officials are also in talks with messenger RNA vaccine makers about potential bird flu shots for humans. Few details have been shared about those negotiations, but HHS said a final announcement is expected soon.

Unlike traditional flu shots, mRNA works by teaching cells to produce a harmless piece of a virus, which triggers an immune response against certain diseases. It is the same technology both Pfizer and Moderna have used in their Covid vaccines.

Chin-Hong said mRNA vaccines could be updated more quickly to match the currently circulating strains of the bird flu. But he said those vaccines have their own challenges, such as needing to be stored at extremely cold temperatures.

In a statement to CNBC, Moderna confirmed that it is involved in negotiations with the government regarding its experimental pandemic influenza shot, mRNA-1018. It targets the exact strain of the virus responsible for the outbreak in dairy cattle.

The biotech company began testing that shot in an early- to mid-stage trial last summer.

Pfizer declined to confirm negotiations with the government. The company said it is continuing to monitor the spread of H5N1 and study its mRNA-based pandemic influenza vaccine candidates in an early trial.

The CDC and its partners, including state and local health departments, use multiple surveillance systems to monitor seasonal influenza and other illnesses. They also have specialized methods to detect and monitor new flu viruses.

Seasonal influenza spreads mostly among humans with predictable peaks during the year, while bird flu spreads mostly among wild birds and other animals.

The CDC said it is looking for the spread of H5N1 to or among people in areas where the virus has been identified in animals or humans. So far, the agency has found "no indicators of unusual influenza activity in people," including H5N1, according to an update on the agency's site from last week.

The CDC also performs ongoing analyses of seasonal and new influenza viruses to identify genetic changes that might allow for them to cause more serious infections in humans, spread more easily to and between people or become less susceptible to vaccines and drugs.

While there is robust testing on the federal, state and local levels, it isfar more difficult for an average person to self-screen and get diagnosed for bird flu like they can for Covid, Chin-Hong said. That's "the big barrier, particularly in the populations that are getting affected now,"he said.

Chin-Hong is referring to farm workers, a large share of whom are immigrants, who may struggle to navigate the U.S. health system due to language barriers and health-care access.

If people do contract the virus, there are a few FDA-approved antiviral drugs for seasonal flu that can be used for bird flu. That includes Tamiflu, which is an oral prescription medication that should be taken within 48 hours of experiencing symptoms.

A Texas dairy farm worker who was diagnosed with bird flu in March was treated with an antiviral drug and recovered, according to a CDC report.

But Pekosz said the antiviral drugs in the nation's stockpile are likely not enough for the vast majority of the population, so manufacturers may be asked to scale up supply.

The average person can protect themselves from bird flu by avoiding any living or dead animals that might be infected, such as livestock or chickens, according to Francesca Torriani, infectious disease specialist with UC San Diego Health.

People who need to make contact with those animals should wear the appropriate mask and eye protection and wash their hands afterward.

Torriani added that pasteurized milk and cheese are likely safer to consume than raw dairy products since the pasteurization process kills harmful bacteria.

See the original post:

Here's how U.S. health officials are responding to bird flu in humans after second case - CNBC

HPV vaccine provides real benefits for men and boys; reduces their risk of head and neck cancers: Study – Hindustan Times

May 25, 2024

Vaccination of boys and men against the human papillomavirus (HPV) reduces their risk of head and neck cancers and other malignancies, a new analysis shows, adding to the vaccine's proven benefit in protecting women from cervical cancer. (Also read | What is Human Papillomavirus and why it can put you at risk of cancer?)

The study of more than 3.4 million people is one of the first long-term analyses of the vaccine's real-world effect on preventing HPV-related cancers of the head and neck, anal areas, penis, vulva, vagina and cervix, researchers said.

Previous studies of the vaccine have focused mainly on cervical cancer. In one large 2020 study from Sweden, for example, cervical cancer rates were 47 per 100,000 in vaccinated women and 94 per 100,000 in unvaccinated women.

The new study, scheduled for presentation at the upcoming American Society of Clinical Oncology meeting in Chicago, included more than 1.7 million volunteers who were vaccinated against HPV since 2010, at some point between ages 9 and 39, and roughly equal numbers of similar unvaccinated volunteers. About 44% were male.

Vaccinated males had lower rates of any HPV-related cancer and of head and neck cancers (3.4 and 2.8 cases, respectively per 100,000 vaccinated patients, compared with 7.5 and 6.3, respectively, per 100,000 unvaccinated patients), the study found.

Smoking was formerly the main driver of many head and neck cancers - such as cancers of the mouth and throat - but today the main cause is HPV infections, ASCO President Dr. Lynn Schuchter said on Thursday at a press briefing. Schucter was not involved in the study.

The new study "extends what we know" and shows that preventing infection with the vaccine helps prevent these additional HPV-related cancers, she added.

Vaccinated females had a lower risk of any HPV-related cancers in the study and, as expected, a lower risk of cervical cancer, compared with unvaccinated females.

Vaccination did not significantly reduce their risks for head and neck cancers and vulvar or vaginal cancer.

Merck's HPV vaccine was approved in 2006 for girls and women ages 9 to 26 and in 2009 for boys and men in that age group. The most recent version, Gardasil 9, has been approved in the U.S. since 2018 for use in children and adults ages 9 through 45.

A separate study to be presented at the ASCO meeting found that between 2011 and March 2020, U.S. uptake of the HPV vaccine rose from 23.3% to 43.0% of the eligible population, improving from 7.8% to 36.4% in males and from 37.7% to 49.4% among females.

Catch your daily dose of Fashion, Taylor Swift, Health, Festivals, Travel, Relationship, Recipe and all the other Latest Lifestyle News on Hindustan Times Website and APPs.

Go here to see the original:

HPV vaccine provides real benefits for men and boys; reduces their risk of head and neck cancers: Study - Hindustan Times

What We’re Reading: Bird Flu Protective Gear; HPV Vaccine Protects Against Head, Neck Cancers; Tobacco Industry … – AJMC.com Managed Markets Network

May 25, 2024

Numerous US Dairy Workers Yet to Receive Protective Bird Flu Gear

Workers, activists, and farmers claimed that many US dairy farms have not yet increased bird flu protections for employees despite the outbreak in cows, according to Reuters. Although the CDC asked states to make protective equipment available to workers after a Texas dairy worker tested positive for bird flu, 7 activists, 3 dairy workers, and 2 lawyers told Reuters that dairy owners have not yet offered equipment to staff who spend 10- to 12-hour days close to cows. Also, the workers said they heard of the new virus affecting cattle through community organizers or the media, not their employers. While farmers downplay the risk of bird flu to workers, epidemiologists are concerned about the risk of more human infections of the virus as it has pandemic potential; this comes amid the recent discovery of a second human bird flu case.

New research found that the human papillomavirus (HPV) vaccine is linked to a drastic reduction in head and neck cancers in adolescent boys and men, according to NBC News. HPV is a sexually transmitted infection responsible for the majority of cervical cancer cases, but it also accounts for up to 70% of head and neck cancers; the National Cancer Institute noted that men are about twice as likely to develop these cancers than women. Initially approved for adolescent girls, the HPV vaccine protects against strains of the virus linked to cervical cancer. However, there is growing evidence that the vaccine also protects against other HPV-related cancers. A new study found that being vaccinated reduced the overall risk of HPV-related cancers in males by 54%, a decrease primarily driven by a decline in head and neck cancers. These findings are not yet published in a peer-reviewed journal, but they will be presented at the American Society of Clinical Oncology (ASCO) conference next week.

The World Health Organization (WHO) recently accused tobacco companies of trying to hook a new generation on nicotine by targeting young people, according to CBC. Amid strict cigarette regulations, tobacco companies have started offering smoking alternatives, like vapes, which they claim are aimed at adult smokers. However, in a joint report, WHO and industry watchdog Stopping Tobacco Organizations and Products (STOP) concluded that these productsare often marketedto youth due to their designs and flavors. WHO explained that tobacco companies target young people through social media and by sponsoring music and sports festivals; this gives the companies platforms to hand out free samples and promote their brands to younger audiences. Although tobacco companies claim they are marketing vapes for adults as an alternative to cigarettes, WHOnotedthat there is insufficient evidence that vapes help people quit smoking; instead, evidence shows that vaping increases traditional cigarette use, especially among youth.

Read the original post:

What We're Reading: Bird Flu Protective Gear; HPV Vaccine Protects Against Head, Neck Cancers; Tobacco Industry ... - AJMC.com Managed Markets Network

Study: HPV vaccines prevent cancer in men as well as women – WPRI.com

May 25, 2024

CARLA K. JOHNSON AP Medical Writer

23 hours ago

FILE - A doctor holds a vial of the human papillomavirus (HPV) vaccine Gardasil in Chicago on Aug. 28, 2006. Research published Thursday, May 23, 2024, by the American Society of Clinical Oncology suggests the HPV vaccine is preventing throat cancer in men, as well as cervical cancer in women, but fewer boys than girls are getting the shots in the United States. (AP Photo/Charles Rex Arbogast, File)

New research suggests the HPV vaccine is preventing cancer in men, as well as in women, but fewer boys than girls are getting the shots in the United States.

The HPV vaccine was developed to prevent cervical cancer in women and experts give it credit, along with screening, forlowering cervical cancer rates.Evidence that the shots are preventing HPV-related cancers in men has been slower to emerge, but the new research suggests vaccinated men have fewer cancers of themouth and throatcompared to those who didnt get the shots. These cancers are more than twice as common in men than in women.

For the study, researchers compared 3.4 million people of similar ages half vaccinated versus half unvaccinated in a large health care dataset.

As expected, vaccinated women had a lower risk of developing cervical cancer within at least five years of getting the shots. For men, there were benefits too. Vaccinated men had a lower risk of developing any HPV-related cancer, such as cancers of the anus, penis and mouth and throat.

These cancers take years to develop so the numbers were low: There were 57 HPV-related cancers among the unvaccinated men mostly head and neck cancers compared to 26 among the men who had the HPV vaccine.

We think the maximum benefit from the vaccine will actually happen in the next two or three decades, said study co-author Dr. Joseph Curry, a head and neck surgeon at the Sidney Kimmel Cancer Center in Philadelphia. What were showing here is an early wave of effect.

Results of the study and a second were released Thursday by the American Society of Clinical Oncology and will be discussed next month at its annual meeting in Chicago. The second study shows vaccination rates rising but males lag behind females in getting the HPV shots.

HPV, or human papillomavirus, is very common and is spread through sex. Most HPV infections cause no symptoms and clear up without treatment. Others develop into cancer, about 37,000 cases a year, according to the Centers for Disease Control and Prevention.

In the U.S., the HPV vaccine has been recommended since 2006 for girls at age 11 or 12, and since 2011 for boys the same age. Catch-up shots are recommended for anyone through age 26 who hasnt been vaccinated.

In the second study, researchers looked at self- and parent-reported HPV vaccination rates in preteens and young adults in a large government survey. From 2011 to 2020, vaccination rates rose from 38% to 49% among females, and among males from 8% to 36%.

HPV vaccine uptake among young males increased by more than fourfold over the last decade, though vaccination rates among young males still fall behind females, said study co-author Dr. Danh Nguyen at the University of Texas Southwestern Medical Center in Dallas.

Parents of boys, as well as girls, should know that HPV vaccines lower cancer risk, said Jasmin Tiro of the University of Chicago Medicine Comprehensive Cancer Center who was not involved in the research. And young men who havent been vaccinated can still get the shots.

Its really important that teenagers get exposed to the vaccine before theyre exposed to the virus, she said.

Read the original:

Study: HPV vaccines prevent cancer in men as well as women - WPRI.com

CDC says mpox vaccines can protect the U.S. from more dangerous virus: What to know – NBC News

May 25, 2024

As concerns mount about a large outbreak of an especially virulent form of mpox in central Africa and an uptick in U.S. cases since early last year, the mpox vaccine appears to give long-term protection, the Centers for Disease Control and Prevention reported Thursday.

In a separate report, the CDC indicated that overall new mpox infections across the U.S. have remained at a steady, low level about 60 cases weekly, compared with 3,000 cases a week at the outbreaks summer 2022 peak in recent months. However, cases so far this year are elevated nationally compared with the same period in 2023 and have seen a sharp increase in New York City.

People who have gotten two doses of the Jynneos mpox vaccine are protected against infection and dont need a booster at this time, according to the CDC.

Public health experts are concerned that the launch of the summer travel season and the upcoming LGBTQ Pride festivals in cities across the country will drive greater sexual connectivity among gay and bi men and potentially hasten mpox transmission.

Christina Hutson, chief of the CDCs Poxvirus and Rabies Branch, and other public health experts told NBC News that this is no time for complacency about mpox (formerly called monkeypox). The various factors that likely have kept the U.S. outbreak relatively in check since late 2022 including vaccination, infection-driven immunity, and sexual behavioral change may be tenuous.

The mpox outbreak is poised to return under the right conditions, said Dr. Jeffrey Klausner, an infectious disease expert at the University of Southern California. Infections rapidly tore around the globe beginning in May 2022 and made that summer a misery for many gay and bisexual men before collapsing worldwide.

Critically, the proportion of at-risk American gay and bi men who are fully vaccinated against mpox is considered inadequate to assure long-term protection for this vulnerable population.

Vaccination is a critical way to help protect yourself and others, Hutson said. Its important that people at risk for mpox exposure who have not previously recovered from mpox including certain gay, bisexual, and other men who have sex with men complete the two-dose Jynneos vaccination series.

On May 16, the CDC published an ominous report about nearly 20,000 recent cases of what is known as clade 1 of mpox that have been documented in the Democratic Republic of Congo, or DRC, since January 2023.

Concerningly, this viral clade appears to be more transmissible and to cause higher rates of severe disease and death compared with clade 2 of mpox, which drove the recent global outbreak. Five percent of those diagnosed with clade 1 in the DRC have died, compared with just 0.2% of the 96,000 people in the global clade 2 outbreak.

To date, there have been no reports of clade 1 cases outside of the handful of African nations where mpox has been endemic for decades. In December, the CDC first alerted health care providers of the possibility that this more harmful viral clade could hit the United States.

Were facing a big, potentially dangerous situation, Ira Longini, a biostatistician at the University of Florida, said of the potential for global spread of clade 1. But we really dont know.

Dr. Boghuma Titanji, an assistant professor at the Emory University School of Medicine, suggested that the Jynneos vaccine will likely provide protection against clade 1. The Jynneos vaccine is approved in the U.S. for mpox regardless of clade.

Its reasonable to anticipate that there would be some immune cross-protection, she said of immunity stemming both from the vaccine and previous infection with clade 2.

A clinical trial of the Jynneos vaccine is ongoing among health care workers in the DRC. It is not expected to be completed until the end of next year.

But the vaccine has not otherwise been rolled out in the DRC, a lost opportunity to help control the nations outbreak and prevent clade 1 from spreading globally, Titanji said.

Dr. Placide Mbala, the head of epidemiology and the global health department at the University of Kinshasa in the DRC, said the nation has seen a lot of interest from global public health leaders in providing such assistance.

But we are still waiting for concrete action, Mbala said.

During the clade 2 outbreak, mpox has overwhelmingly transmitted via intercourse, both oral and anal, between men. Transgender people have also been disproportionately affected. The virus has not transmitted readily through the air or surfaces, in health care settings, or through casual, nonsexual contact.

In an interview earlier this year, CDC epidemiologist Dr. Jennifer McQuiston said mpox needs to be thought about as an STD. The good news is its a preventable STD.

Multiple studies of real-world uptake of the Jynneos vaccine have suggested that receiving both doses is associated with a 66% to 89% lower infection rate and one dose is 36% to 75% effective.

In one of the new CDC reports, agency investigators analyzed demographic data and clinical characteristics concerning 271 mpox cases from the U.S. outbreaks outset in May 2022 to May 2024 among fully vaccinated people in 27 U.S. jurisdictions that provided sufficient related data.

According to a CDC official, the agency estimates that only 0.1% of the fully vaccinated population developed a breakthrough infection. Reported such cases amounted to 0.8% of all 32,819 mpox diagnoses nationally. Thirteen percent of mpox cases were in partially vaccinated people.

The CDC estimates that 2 million men in the U.S. are at significant risk of mpox because they engage in sex with multiple male partners or otherwise are HIV positive; people with HIV have had a high mpox diagnosis rate. Of the overall group of at-risk gay and bi men, only approximately 25% have been fully vaccinated and an additional 14% have received one Jynneos shot.

In keeping with previous studies, the CDCs new report found that full vaccination was associated with less severe disease and a lower hospitalization rate.

All 56 mpox deaths were among unvaccinated people.

Recent research has raised concerns that the antibodies Jynneos prompts wane over time. But the CDC investigators found evidence that, at least so far, the vaccines actual protection against infection hasnt waned, possibly due to whats known as innate or cell-based immunity.

Shortly after the vaccine was first rolled out in midsummer 2022, U.S. health authorities began stretching the temporarily short supply by changing its administration from a traditional subcutaneous (under the skin) shot to an intradermal (within the skin) shot that allowed for a much lower dose.

The new CDC report found no evidence that this vaccine-application shift compromised vaccine effectiveness.

A separate new CDC analysis of recent U.S. mpox diagnoses found the virus is still overwhelmingly seen among gay and bi men. Just 0.4% of recent cases were in people younger than 18.

Between October and April, 1,802 probable and confirmed mpox cases were reported to the CDC by 42 jurisdictions for an average weekly rate, which remained essentially steady, of 59 cases. By stark contrast, the nation saw 2,000 to 3,300 weekly cases at the outbreaks peak between mid-July and late August 2022.

And yet, CDC records show that the nearly 750 mpox cases seen this year through mid-April is more than twice the figure reported during the comparable period in 2023. New York City has seen a nearly five-fold case-rate increase between these two periods, with 191 cases thus far in 2024.

As for concerns about how a U.S. outbreak of clade 1 might transpire, infectious disease experts said they could only speculate whether higher quality health care, for one, might yield a lower death rate than in the DRC. Global clade 2 deaths have largely occurred among people with compromised immune systems, mostly due to untreated HIV.

Other unknowns include how and among which groups clade 1 might tend to transmit in Western nations. The DRC outbreak has occurred both in men with multiple male sex partners and in female sex workers and their contacts. And two- thirds of the DRCs clade 1 outbreak has been in people under age 16; only a bit over 1% of the global clade 2 outbreak was in minors.

Epidemiologists see evidence of sustained person-to-person transmission in one DRC province, where cases are primarily in adults.

While this transmission apparently has largely been through sex, compared with clade 2 of mpox clade 1 shows signs that it can nevertheless transmit more readily absent sexual contact. However, clade 1 still seems to require close personal contact, and nonsexual transmission appears largely limited to household settings. Also, the substantial transmission in children could be driven in part, the recent CDC report suggested, by multiple spillovers from wild animals encountered by young people in rural settings.

CDC officers believe that widespread transmission of clade 1 among children in the U.S. is much less likely, owing to a lack of an animal reservoir, less- crowded living quarters, and better cleaning and hygiene.

Emorys Titanji reported worries that the gay and bi men she cares for quickly lost interest in mpox vaccination after the outbreak stopped being a primary concern for them. During the fall of 2022, the nations weekly distribution rate of Jynneos shots plummeted in tandem with the mpox case rate.

Since then, no substantial progress has been made in raising the proportion of at-risk gay and bi men who have received both Jynneos doses.

If youre not yet vaccinated and you meet criteria, go and get vaccinated, Titanji said. We cant be complacent about the response now moving forward.

Benjamin Ryan is independent journalist specializing in science and LGBTQ coverage. He contributes to NBC News, The New York Times, The Guardianand Thomson Reuters Foundation and has also written for The Washington Post, The Nation, The Atlantic and New York.

See the article here:

CDC says mpox vaccines can protect the U.S. from more dangerous virus: What to know - NBC News

The HPV vaccine is linked to lower rates of head and neck cancer in males, study finds – NBC Chicago

May 25, 2024

The HPV vaccine is linked to a drastic reduction in head and neck cancers in adolescent boys and men, new research finds.

HPV, or human papillomavirus, is a sexually transmitted infection responsible forvirtually all cases of cervical cancer. But thevirus is also linked to a number of other cancers, including penile, anal and vaginal cancers.

According to NBC News it also accounts for themajority up to 70% of head and neck cancers, which affect the throat and mouth. Men are abouttwice as likelyto develop these cancers than women, according to the National Cancer Institute.

The HPV vaccine, initially approved for adolescent girls, protects against strains of the virus linked to cervical cancer and has been found tosignificantly reduce rates of the cancer. But theres growing evidence that the vaccine also protects against other HPV-related cancers.

We want males to be thinking about HPV vaccination not just as something that protects female patients, but also male patients, said Jefferson DeKloe, a research fellow in the department of otolaryngologyat Thomas Jefferson University, who specializes in head and neck surgery and who co-authored the research.

The findings will be presented next week at the American Society of Clinical Oncology conference and have not yet been published in a peer-reviewed journal.

Prior researchshowed a downward trend in oral infections with HPV strains known to cause cancer. That was a promising sign, said Dr. GlennJ. Hanna, a medical oncologist at the Dana-Farber Cancer Institutes Center for Head and Neck Oncology, who was not involved in the new research.

If we can lower the infection rate, we would hope that we would see what we are seeing now, a decline in cancer rates, Hanna said. This is an important evolution of the story.

The new study analyzed health records from a national database that included nearly 3.5 million people in the United States ages 9 to 39 who had received any vaccination HPV or otherwise from 2010 through 2023. About 1.5 million were male, half of whom had been vaccinated against cancer-causing strains of HPV. Nearly 1 million were females who had been vaccinated against HPV.

The researchers compared the rates of HPV-linked cancers including head and neck, anal, penile, and cervical cancers in people who had received the HPV vaccine to those who hadnt. They found being vaccinated reduced the overall risk of HPV-related cancers in males by 54%, a decrease driven primarily by a drop in head and neck cancers. Females were about 30% less likely to develop any type of HPV-related cancer, including cervical cancer.

Most cases of head and neck cancer are in people older than 50. Since the U.S. is only about a decade into widespread HPV vaccination in both males and females, the vaccinated generation hasnt reached this age yet. HPV typically infects younger people and takes decades for chronic infection to lead to cancer.

These are the early results of a larger phenomenon we are going to watch play out over the next 20 or 30 years, DeKloe said, noting that experts dont expect to see thefull effect HPV vaccination has on cancer ratesuntil the largely vaccinated generation is older.

A second study, which will also be presented at the ASCO conference next week and is not yet published in a peer-reviewed journal, found that HPV vaccination rates have been on the rise in the U.S. from 2011 through early 2020, including in all racial and ethnic groups.

HPV vaccination wasnt recommended for males until 2011, five years after the Centers for Disease Control and Prevention recommended the vaccine series for girls. The HPV vaccine is nowrecommendedfor all adolescents starting as young as age 9, but can also be given to adults up to age 45.

In the new study, which included children and young adults ages 9 to 26, the increase was largely driven by growing HPV vaccine uptake among males. Although overall HPV vaccination rates among males still lag behind females about 36% compared to about 50% of those in the 9 to 26 age group these rates are accelerating.

The gap is narrowing between males and females and eventually I would hope that they would meet up, said Dr. Danh Nguyen, a resident physician at University of Texas Southwestern Medical Center, who led the research.

Although vaccination efforts have focused on adolescents, adults should also consider getting vaccinated if they werent when they were younger, said Dr. Nancy Lee, service chief of head and neck radiation oncology at Memorial Sloan Kettering Cancer Center in New York City, who was not involved with either study.

If you are in your 20s or 30s, you can still get the vaccination. Even if you are 45, there is no reason you cannot get vaccinated because we have a population that lives a long time, Lee said.

Nguyen said its important that conversations about HPV vaccination continue to focus on the prevention of all cancers, including head and neck cancers that are more prevalent in men, rather than solely on cervical cancer prevention.

Hanna said stigma around HPV being a sexually transmitted infection has made discussions aroundvaccinating adolescentsa sticky subject in the past, but that clear data showing the impact vaccination rates have on HPV-related cancers is shifting the narrative.

HPV vaccination is cancer prevention, Hanna said. The bottom line is that we are preventing cancers broadly by getting people vaccinated younger.

This story first appeared on NBCNews.com. More from NBC News:

See the article here:

The HPV vaccine is linked to lower rates of head and neck cancer in males, study finds - NBC Chicago

Meet the Israeli doctor who revealed a major COVID vaccine side-effect – Ynetnews

May 25, 2024

The State Comptroller's report published Tuesday criticized the state's handling of the coronavirus epidemic, including the fact that the Health Ministry did not receive or analyze reports of side effects of the vaccines and the lack of antigen kits.

Along with the criticism, the auditor pointed to an in-depth investigation of one of the side effects of the vaccine, myocarditis, thanks to the vigilance of Professor Dror Mevorach, who ran the coronavirus department at the Hadassah Medical Center and was the first doctor in the world to detect the disease among those vaccinated against the virus.

2 View gallery

Professor Dror Mevorach ran the coronavirus department at the Hadassah Medical Center

(Photo: Yuval Chen )

"A patient with myocarditis appeared during morning rounds," Mevorach said about the discovery process of the side effect. "I asked him about the specific things that happened in the two weeks before the visit and he told me that he had received a vaccine against the coronavirus. I thought we might investigate the possible connection. I followed cases of myocarditis that were hospitalized in Hadassah and to my surprise I discovered that nine out of the 10 patients I examined received a vaccine right before hospitalization. So, I had no doubt at that moment it was related to the vaccine. However, the Health Ministry took my message seriously and we set up a committee on the matter in a very intensive way and, as a result, we published three articles, which are milestones in the world literature and showed the clear connection between the vaccine, and especially a second vaccination among young men, and myocarditis. This is considered the main side effect related to the vaccine and which everyone agrees on, while there is no general agreement regarding other side effects."

One of the articles authored by Mevorach, director of the Rheumatology-Immunology Department at Hadassah Ein Kerem Hospital, was published in the prestigious New England Journal of Medicine. He said that he is currently conducting a follow-up study.

2 View gallery

Israeli patient receives coronavirus vaccine

(Photo: Vererd Shutzman /Shutterstock)

"I am following the phenomenon among more than 100 people to understand the phenomenon over time. The incidence is one in 5,000 or 6,000 vaccinated young people. Unfortunately, there was one death, but 90% of people recover well and 5% can have long-term complications." According to the doctor, his research continues to receive interest and attention around the world.

Given the information you have today, would you recommend blanket vaccination for all young people?

"I would recommend young people to get vaccinated, but warn them and better monitor them. Today I would be less enthusiastic about vaccinating young men, but at the time it was a more serious disease that put people at risk, and it made sense to give it. This is not the position of the Ministry of Health, but my position."

Could it be that we rushed to vaccinate everyone indiscriminately?

"We rushed to vaccinate comprehensively, and in the end it was necessary. The epidemic was at its peak all over the world, and these vaccinations saved millions. Today we have more information and things should have been done with discretion, but that does not mean that things were not done properly back then. There was a decision based on partial information and, as happens in these situations, precisely after the approval, additional things are revealed."

We also saw yesterday on social media that coronavirus deniers as well as vaccine opponents are getting a boost from this report. Can you address this claim?

"Ultimately, we want to create public trust. We are truly committed to the truth. We are not committed to selling Pfizer vaccines or even committed to the policy of the Health Ministry. We respect it, but we are committed first to the medical truth. The public has the right to know, so I did not hesitate when I saw this to say that there is a problem of myocarditis; it is relatively rare but it exists. A lot of people in the system are against the vaccine. We are not afraid of what will scare people, we are committed to the medical truth. The public's trust increases significantly and fewer turn to fake news, which unfortunately some people like. I don't know why they do it; This is a phenomenon in itself that can be studied."

Mevorach noted that he did not agree with the recommendation regarding a blanket vaccination for the fourth and fifth time. "I think that from the fourth and fifth vaccination, with the mutation of the disease, we should stop for a moment and not do anything just because the U.S. is doing it, because it took the U.S. a long time to realize that there is inflammation of the heart muscle as a side effect of the vaccine. There is a outline for the team for the treatment of epidemics. It is supposed to examine the pros and cons and invite people. I attended some of these meetings. The Health Ministry worked well on the issue of myocarditis. The report indicates that there are things that did not work, for example there were many women who claimed that it causes menstrual disorders and it was not treated in the first stage sufficiently or there was disdain for the claim itself. This is not the appropriate way to handle this. These claims should be respected and today there is more evidence that if the vaccine is given in the first part of the cycle, it causes an extension of the menstrual period and other issues. The claims about side effects should be respected."

Here is the original post:

Meet the Israeli doctor who revealed a major COVID vaccine side-effect - Ynetnews

3 Things You Need to Know If You Buy Novavax Today – Yahoo Finance

May 25, 2024

Novavax (NASDAQ: NVAX) stock has both soared and plummeted at times in recent years. Investors initially bet on the biotech company to be a winner in the coronavirus vaccine race, sending the stock to a 2,700% gain back in 2020. But when Novavax fell behind on the road to commercialization, the shares declined -- and even the eventual regulatory approval and market entry of that vaccine didn't much help.

In recent times, though, Novavax has taken steps to improve its profitability prospects. And in the wake of big news earlier this month, the shares surged again, giving investors hope that the company may be just at the beginning of a period of positive momentum. Is it time to buy? Before making any decisions, here are three things you need to know.

Novavax's vaccine didn't enter the market until after the inoculations developed by Moderna and Pfizer had already taken dominant market shares. This meant it missed out on the biggest revenue opportunity, and it had difficulty competing with these established leaders.

But its recent deal with Sanofi could supercharge its revenue growth. The pharmaceutical giant is the global leader in flu vaccines, and has the commercial infrastructure and experience to bring one to the attention of healthcare providers. That's why Sanofi's agreement to co-commercialize Novavax's vaccine as of next year is such positive news for the smaller company.

In addition, Sanofi acquired rights to use the Novavax vaccine as a component in multi-inoculation shots that combine a COVID-19 booster with flu vaccines or other vaccines. If Sanofi is able to generate strong sales of such combo vaccines, that would result in the biotech reaping significant royalty payments.

Of course, COVID-19 vaccine revenue is unlikely to reach the levels seen during the public health crisis. As the threat has receded, demand for COVID vaccines has declined, so this may be a steady revenue story rather than an explosive one.

Novavax, after bringing in lower-than-expected vaccine revenue, last year issued a "going concern" warning that closing its doors was a possibility. At the same time, the company launched a major cost-cutting plan.

The Sanofi agreement, including a $500 million upfront payment and up to $700 million in milestone payments, allowed Novavax to drop that warning, which significantly reassured investors.

And Novavax's own efforts are another reason to believe the company is progressing along the right path. It reduced its research and administrative expenses by 50% year over year in the first quarter, and is targeting expenses of $700 million to $750 million this year. The biotech also is ready to launch a new phase in its cost-reduction efforts next year with the goal of lowering annual expenses to $500 million.

Story continues

So, Novavax on its own made considerable progress on the cost-cutting path. Between that and the Sanofi investment, the company's recovery story may be strengthening.

During the past vaccination season, people showed much greater interest in flu shots than in COVID jabs. About 29% of U.S. adults opted for a coronavirus vaccine or booster, while 47% got the annual flu shot, according to a Gallup survey.

And that's why Novavax's combination coronavirus and flu vaccine candidate may be so important. It could appeal to the population that already goes for annual flu shots, offering them the convenience of two shots in one.

Novavax may even multiply its combination vaccine successes thanks to the deal with Sanofi. First, Novavax is continuing to develop its own combined COVID/flu candidate, which is set to enter phase 3 trials in the second half of this year. Second, as mentioned above, Sanofi now has the rights to combine the Novavax coronavirus vaccine with its flu vaccines -- and if this produces a commercialized product, Sanofi would pay royalties to Novavax.

So, Novavax could generate revenue from more than one combination vaccine down the road.

Novavax stock was a risky buy just a few months ago. But today, the situation looks much brighter. Of course, it will take time for Novavax to carve out market share in the coronavirus vaccine market, and sales from potential combined vaccines aren't right around the corner -- those candidates must successfully make it through clinical trials and win approval first.

But right now, Novavax is moving in the right direction and is doing so with a powerful partner. So if you're looking for a promising recovery story buy, Novavax may fit the bill.

Before you buy stock in Novavax, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the10 best stocks for investors to buy now and Novavax wasnt one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider whenNvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, youd have $580,722!*

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. TheStock Advisorservice has more than quadrupled the return of S&P 500 since 2002*.

See the 10 stocks

*Stock Advisor returns as of May 13, 2024

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Moderna. The Motley Fool has a disclosure policy.

3 Things You Need to Know If You Buy Novavax Today was originally published by The Motley Fool

Original post:

3 Things You Need to Know If You Buy Novavax Today - Yahoo Finance

The clinical and economic costs associated with regional disparities in varicella vaccine coverage in Italy over 50 years … – Nature.com

May 25, 2024

World Health Organization. Varicella and herpes zoster vaccines: WHO position paper, June 2014. Wkly Epidemiol. Rec. 89(25), 265288 (2014).

Google Scholar

Gershon, A. A. et al. Varicella zoster virus infection. Nat. Rev. Dis. Primers. 1(1), 18 (2015).

Article Google Scholar

Varela, F. H., Pinto, L. A. & Scotta, M. C. Global impact of varicella vaccination programs. Hum. Vaccin. Immunother. 15(3), 645657 (2019).

Article PubMed Google Scholar

Prymula, R. et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial. Lancet 1, 13131324 (2014).

Article Google Scholar

Kuter, B. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr. Infect. Dis. J. 23(2), 132137 (2004).

Article PubMed Google Scholar

Baxter, R. et al. Long-term effectiveness of varicella vaccine: A 14-year, prospective cohort study. Pediatrics 131(5), 13891396 (2013).

Article Google Scholar

Marin, M., Marti, M., Kambhampati, A., Jeram, S. M. & Seward, J. F. Global varicella vaccine effectiveness: A meta-analysis. Pediatrics 137(3), 1 (2016).

Article Google Scholar

Merck & Co., Inc., Rahway, NJ, USA. PROQUAD(R) (Measles, Mumps, Rubella and Varicella Virus Vaccine Live) [Prescribing Information]. 02 2023. [Online]. Available: https://www.merck.com/product/usa/pi_circulars/p/proquad/proquad_pi_4171.pdf. [Accessed 26 05 2023].

GlaxoSmithKline Inc. PRIORIX-TETRA (Combined measles, mumps, rubella and varicella vaccine, live, attenuated) [Product Monograph]. 08 2019. [Online]. Available: https://ca.gsk.com/media/6253/priorix-tetra.pdf. [Accessed 26 05 2023].

DAncona, F., DAmario, C., Maraglino, F., Rezza, G. & Iannazzo, S. The law on compulsory vaccination in Italy: An update 2 years after the introduction. Eurosurveillance 24(26), 1900371 (2019).

Article PubMed PubMed Central Google Scholar

Spoulou, V. et al. Implementing universal varicella vaccination in Europe: The path forward. Pediatr. Infect. Dis. J. 38(2), 181188 (2019).

Article PubMed Google Scholar

Trucchi, C., Gabutti, G., Rota, M. C. & Bella, A. Burden of varicella in Italy, 20012010: analysis of data from multiple sources and assessment of universal vaccination impact in three pilot regions. J. Med. Microbiol. 64(11), 13871394 (2015).

Article PubMed Google Scholar

Amodio, E. et al. Varicella vaccination as useful strategy for reducing the risk of varicella-related hospitalizations in both vaccinated and unvaccinated cohorts (Italy 20032018). Vaccine 38, 56015606 (2020).

Article PubMed Google Scholar

Azzari, C. et al. The cost-effectiveness of universal varicella vaccination in Italy: A model-based assessment of vaccination strategies. Clinicoecon. Outcomes Res. 12, 273 (2020).

Article CAS PubMed PubMed Central Google Scholar

Wutzler, P. et al. Varicella vaccinationthe global experience. Expert. Rev. Vaccines 16(8), 883843 (2017).

Article Google Scholar

Marin, M. et al. Decline in severe varicella disease during the United States varicella vaccination program: hospitalizations and deaths, 19902019. J. Infect. Dis. 226(Suppl 4), S407S415 (2022).

Article PubMed Google Scholar

Direzione generale della prevenzione sanitaria, "Vaccinazioni dell'et pediatrica e dell'adolescenza - Coperture vaccinali," 19 10 2022. [Online]. Available: https://www.salute.gov.it/portale/documentazione/p6_2_8_3_1.jsp?lingua=italiano&id=20. [Accessed 26 05 2023].

European Centre for Disease Prevention and Control (ECDC). Vaccine Scheduler, Italy: recommended vaccinations. 04 11 2021. [Online]. Available: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByCountry?SelectedCountryId=103&IncludeChildAgeGroup=true&IncludeChildAgeGroup=false&IncludeAdultAgeGroup=true&IncludeAdultAgeGroup=falseLast. [Accessed 26 05 2023].

Agenzia Italiana del Farmaco. Linea guida per la compilazione del Dossier a supporto della domanda di rimborsabilit e prezzo di un medicinaleEstratto sezione E. Agenzia Italiana del Farmaco, Roma (2020).

United Nations Childrens Fund. The State of the World's Children 2023: For every child, vaccination. UNICEF InnocentiGlobal Office of Research and Foresight, Florence (2023).

Bozzola, E. et al. Pediatric hospitalization for varicella in an Italian pediatric hospital: How much does it cost?. Int. J. Environ. Res. Public Health 18(22), 12053 (2021).

Article CAS PubMed PubMed Central Google Scholar

Jang, S. et al. Factors shaping the COVID-19 epidemic curve: A multi-country analysis. BMC Infect. Dis. 21, 1032 (2021).

Article CAS PubMed PubMed Central Google Scholar

Buonomo, B. & Marca, R. Effects of information-induced behavioural changes during the COVID-19 lockdowns: The case of Italy. R. Soc. Open Sci. 7, 201635 (2020).

Article ADS CAS PubMed PubMed Central Google Scholar

World Health Organization. Immunization coverage. 14 07 2022. [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/immunization-coverage. [Accessed 19 05 2023].

World Health Organization. Global partners annouce a new effort"The Big Catch-up"to vaccinate millions of children and restore immunization progress lost during the pandemic 24 04 2023. [Online]. Available: https://www.who.int/news/item/24-04-2023-global-partners-announce-a-new-effort-the-big-catch-up-to-vaccinate-millions-of-children-and-restore-immunization-progress-lost-during-the-pandemic. [Accessed 19 05 2023].

Wolfson, L. J. et al. Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model. PLoS One 14(8), 1 (2019).

Article Google Scholar

Heininger, U. et al. Health impact and cost-effectiveness assessment for the introduction of universal varicella vaccination in Switzerland. Pediatr. Infect. Dis. J. 40(6), 217221 (2021).

Article Google Scholar

Pawaskar, M., Burgess, C., Pillsbury, M., Wislff, T. & Flem, E. Clinical and economic impact of universal varicella vaccination in Norway: A modeling study. PLoS ONE 16(7), 1 (2021).

Article Google Scholar

Burgess, C., Kujawski, S., Lapornik, A., Bencina, G. & Pawaskar, M. The long-term clinical and economic impact of universal varicella vaccination in Slovenia. J. Health Econ. Outcomes Res. 9(2), 95102 (2022).

Article PubMed PubMed Central Google Scholar

Sharomi, O. et al. Modeling the impact of exogenous boosting and universal varicella vaccination on the clinical and economic burden of varicella and herpes zoster in a dynamic population for England and Wales. Vaccines 10(9), 1416 (2022).

Article PubMed PubMed Central Google Scholar

Kujawski, S. A. et al. "The health and economic impact of switching vaccines in universal varicella vaccination programs using a dynamic transmission model: An Israel case study. Hum. Vaccines Immunother. 212, 4784 (2022).

Google Scholar

Maman, K. et al. The value of childhood combination vaccines: From beliefs to evidence. Hum. Vaccines Immunother. 11(9), 21322141 (2015).

Article Google Scholar

Talbird, S. E. et al. Understanding the role of exogenous boosting in modeling varicella vaccination. Expert Rev. Vaccines 17(11), 10211035 (2018).

Article CAS PubMed Google Scholar

Burgess, C., Samant, S., Fevre, T., Schade Larsen, C. & Pawaskar, M. Universal varicella vaccination in Denmark: Modeling public health impact, age-shift, and cost-effectiveness. PLOS Global Public Health 3(4), e0001743 (2023).

Article PubMed PubMed Central Google Scholar

Pillsbury, M., Carias, C., Samant, S., Greenberg, D. & Pawaskar, M. Comparison of performance of varicella vaccines via infectious disease modeling. Vaccine 40(29), 39543962 (2022).

Article CAS PubMed Google Scholar

Scalone, L., Cortesi, P. A., Ciampichini, R., Cesana, G. & Mantovani, L. G. Health Related Quality of Life norm data of the general population in Italy: Results using the EQ-5D-3L and EQ-5D-5L instruments. Epidemiol. Biostat. Public Health 12(3), e11457 (2015).

Google Scholar

De Donno, A. et al. Has VZV epidemiology changed in Italy? Results of a seroprevalence study. Hum. Vaccines Immunother. 13(2), 385390 (2017).

Article Google Scholar

G. Gabutti, M. C. Rota, M. Guido, A. De Donno, A. Bella, M. L. Ciofi (2008) The epidemiology of varicella zoster virus infection in Italy. BMC Public Health 8:372.

Gialloreti, L. E. et al. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: A retrospective, population-based study. BMC Infect. Dis. 10(1), 230 (2010).

Article PubMed PubMed Central Google Scholar

Alicino, C. et al. Incidence of herpes zoster and post-herpetic neuralgia in Italy: Results from a 3-years population-based study. Hum. Vaccines Immunother. 13(2), 399404 (2017).

Article Google Scholar

Instituto Nazionale di Statistica,, "I.Stat," 2023. [Online]. Available: http://dati.istat.it/Index.aspx. [Accessed 26 05 2023].

Eurostat, "Real GDP per capita," 25 05 2023. [Online]. Available: https://ec.europa.eu/eurostat/databrowser/view/sdg_08_10/default/table?lang=en. [Accessed 26 05 2023].

Barbieri, E. et al. The economic burden of pneumococcal disease in children: A population-based investigation in the Veneto region of Italy. Children 9(9), 1347 (2022).

Article PubMed PubMed Central Google Scholar

Ministero della Salute. DPCM 12 gennaio 2017, Allegato 4 (Ministero della Salute, 2017).

Google Scholar

Coudeville, L., Paree, F., Lebrun, T. & Sailly, J. C. The value of varicella vaccination in healthy children: Cost-benefit analysis of the situation in France. Vaccine 17(2), 142151 (1999).

Article CAS PubMed Google Scholar

Coudeville, L., Brunot, A., Giaquinto, C., Lucioni, C. & Dervaux, B. Varicella vaccination in Italy: An economic evaluation of different scenarios. Pharmacoeconomics 22(13), 839855 (2004).

Article PubMed Google Scholar

Fornaro, P. et al. Epidemiology and cost analysis of varicella in Italy: Results of a sentinel study in the pediatric practice. Pediatr. Infect. Dis. J. 18(5), 414419 (1999).

Article CAS PubMed Google Scholar

Giaquinto, C. et al. Epidemiology and outcomes of varicella in Italy: results of a prospective study of children (014 years old) followed up by pediatricians (Pedianet study). Annali di Igiene: Medicina Preventiva e di Comunita 14(4 Suppl 6), 2127 (2002).

CAS PubMed Google Scholar

Ministero dell'Economia e delle Finanze, "Libro verde sulla spesa pubblica. Spendere meglio: alcune prime indicazioni," 2007. [Online]. Available: https://www.mef.gov.it/ministero/commissioni/ctfp/documenti/Libro_verde_spesa_pubblica.pdf. [Accessed 26 05 2023].

Farmadati Italia,, "Farmadati Italia," 2022. [Online]. Available: https://www.farmadati.it/. [Accessed 26 10 2022].

Schink, T., Holstiege, J., Kowalzik, F., Zepp, F. & Garbe, E. Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+ V vaccination. Vaccine 32(6), 645650 (2014).

Article CAS PubMed Google Scholar

Ministero Della Salute. Gazzetta Ufficiale, Serie Generale n. 23 del 2812013: Supplemento Ordinario n. 8. 2013. 128 2013. 28 01 2013. [Online]. Available: https://www.gazzettaufficiale.it/eli/gu/2013/01/28/23/so/8/sg/pdf. [Accessed 26 05 2023].

Riera-Montes, M. et al. Estimation of the burden of varicella in Europe before the introduction of universal childhood immunization. BMC Infect. Dis. 17(1), 353 (2017).

Article PubMed PubMed Central Google Scholar

Baldo, V. et al. Varicella: Epidemiological aspects and vaccination coverage in the Veneto Region. BMC Infect. Dis. 9(1), 150 (2009).

Article PubMed PubMed Central Google Scholar

Originally posted here:

The clinical and economic costs associated with regional disparities in varicella vaccine coverage in Italy over 50 years ... - Nature.com

HPV Vaccines Associated With Lower Cancer Risk in Younger Adults – Curetoday.com

May 25, 2024

People younger than 40 who received a human papillomavirus (HPV) vaccination saw lower rates of cancers often caused by HPV, such as oropharyngeal and cervical cancer, according to findings of a retrospective analysis.

Data presented at a press briefing ahead of the 2024 ASCO Annual Meeting showed that vaccinated female patients experienced statistically significant lower rates of all HPV-related cancers and cervical cancer compared with unvaccinated patients. Differences in the rates of vulvar/vaginal cancers and head and neck cancers did not reach statistical significance, and data for anal cancer were not sufficient for analysis.

Study highlights:

In male patients, statistically significant lower rates of all HPV-related cancers and head and neck cancers were observed for vaccinated patients versus unvaccinated patients. Data were not sufficient to analyze the rates of penile and anal cancers.

Our study showed that patients under the age of 40 [who] were vaccinated for HPV could have lower rates of cancer that are typically caused by HPV, including oropharyngeal cancer and cervical cancer, Jefferson DeKloe, a medical student at Western Michigan University in Kalamazoo and a research fellow at Thomas Jefferson University in Philadelphia, said during the press briefing.

HPV is known to cause cancers in the oropharynx and cervix, as well as in anal and genital regions. HPV vaccines have demonstrated the ability to prevent this infection, and they are recommended for males and females between 9 and 26 years of age. Additionally, patients between 27 and 45 years of age can also receive this vaccine. However, the rates of HPV vaccination in the United States are lower compared with the rates of vaccination for other communicable diseases.

To further study the rates of HPV-related cancers in vaccinated and unvaccinated individuals, DeKloe and colleagues conducted a retrospective analysis using data from the TriNetX Databases US Collaborative Network, which comprised information from deidentified electronic health records for 90 million patients at 63 US health care organizations. The study included patients between 9 and 39 years of age.

Patients were divided into two cohorts. The first included patients who received an HPV vaccine between 2010 and 2023, and the second consisted of patients who received any other vaccine in the same period but were not administered an HPV vaccine.

The cohort of patients who received HPV vaccines included 760,540 males and 945,999 females. The other vaccination cohort comprised 760,539 males and 945,943 females. Patients in the two cohorts were matched for age, race/ethnicity and body mass index (BMI), and investigators examined cancer outcomes at least five years following vaccination.

Investigators also analyzed the correlation between vaccination history and cervical dysplasia. They identified female patients between 21 and 39 years of age who underwent pap testing, excluding patients with a prior history of abnormal findings on a pap smear. Both the HPV-vaccinated and the HPV-unvaccinated cohort included 41,676 patients. After matching for age, race/ethnicity and BMI, investigators examined the rates of dysplasia (the presence of abnormal cells, according to the National Cancer Institute), carcinoma in-situ (CIS, when abnormal cells havent spread to nearby tissue, according to the National Cancer Institute), loop electrosurgical excision procedure (LEEP, use of a heated wire to remove abnormal tissue from a womans lower genital tract, according to Johns Hopkins Medicine) and conization (the removal of a cone-shaped piece of abnormal tissue from the cervix, according to the National Cancer Institute).

Findings showed that a statistically significant difference was not observed between HPV-vaccinated and -unvaccinated patients regarding atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesions (abnormal cells that form on the surface of some organs, according to the National Cancer Institute). However, statistically significant lower rates of high-grade squamous intraepithelial lesions, CIS, abnormal pap findings and conization/LEEP were observed for HPV-vaccinated patients versus unvaccinated patients.

For more news on cancer updates, research and education, dont forget tosubscribe to CUREs newsletters here.

The rest is here:

HPV Vaccines Associated With Lower Cancer Risk in Younger Adults - Curetoday.com

Page 29«..1020..28293031..4050..»